Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LF1U
|
|||
| Former ID |
DCL000422
|
|||
| Drug Name |
Flavopiridol
|
|||
| Synonyms |
FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1], [2] | |
| Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Discontinued in Phase 3 | [3], [4] | ||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H20ClNO5
|
|||
| Canonical SMILES |
CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O
|
|||
| InChI |
1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1
|
|||
| InChIKey |
BIIVYFLTOXDAOV-YVEFUNNKSA-N
|
|||
| CAS Number |
CAS 146426-40-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
606623, 830646, 837792, 7886735, 8035270, 11041362, 14757147, 39320467, 46391640, 46391762, 46507266, 49854007, 50064452, 51029203, 53790160, 57359202, 85177022, 99437041, 104234154, 113870851, 124757102, 125163906, 126671493, 126731324, 127338259, 127338260, 127338261, 127338262, 127338263, 131480733, 134338802, 135064370, 135626623, 136085824, 136367366, 136920327, 137002692, 142106966, 152258050, 160646888, 160966614, 162011554, 164786749, 172818888, 172913786, 175437711, 176236286, 177748773, 178102307, 180371632
|
|||
| ChEBI ID |
CHEBI:47344
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclin-dependent kinase (CDK) | Target Info | Inhibitor | [5] |
| Cyclin-dependent kinase 9 (CDK9) | Target Info | Inhibitor | [2] | |
| Myophosphorylase (PYGM) | Target Info | Inhibitor | [5] | |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| Reactome | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | |||
| WikiPathways | Cardiac Hypertrophic Response | |||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
| Host Interactions of HIV factors | ||||
| HIV Life Cycle | ||||
| IL-9 Signaling Pathway | ||||
| RNA Polymerase II Transcription | ||||
| MicroRNAs in cardiomyocyte hypertrophy | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5680). | |||
| REF 4 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
| REF 5 | Pharma & Vaccines. Product Development Pipeline. April 29 2009. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.